Trial of the ophthalmic solution of PPAR alpha for clinical application

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18859
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56060:Ophthalmology-related
• Research Institution: Nippon Medical School
• Principal Investigator: Takeshi Arima 日本医科大学, 医学部, 講師 (00823113)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: PPARα / PPARβ / PPARγ

Outline of Final Research Achievements

In this study, PPARβ/δ and PPARγ, were similarly administered to eye drops, and their effects on wound healing were evaluated. PPARβ/δ agonist eye drops inhibited inflammation while promoting angiogenesis. When PPARβ/δ agonist eye drops were administered to the normal cornea, angiogenesis did not occur.
The PPARγ agonist ophthalmic solution enhanced its action and suppressed fibrosis more when used as a combination drug with PPARα. Each PPAR and PPAR combination drug has the potential to become a candidate for a new therapeutic strategy for intractable eye diseases such as neovascular glaucoma and diabetic retinopathy, and we will continue our research.

Free Research Field

角膜創傷治癒、網膜血管新生

Academic Significance and Societal Importance of the Research Achievements

PPARαは角膜上皮細胞、網膜内顆粒層、血管内皮細胞 に多く、PPARβ/δは角膜上皮細胞、角膜内皮細胞に、そしてPPARγは角膜上皮細胞、炎症浸潤細胞に多く発現を認めた。局在と役割には相関関係があり、網膜内顆粒層に発現の多いPPARαに関して、硝子体内注射による網膜血管新生病変への新規治療法となる可能性がある。PPARβ/δアゴニストに関しては、角膜内皮細胞に発現が多くKi67の活性化を伴う細胞分裂能の促進を認める点から、角膜内皮細胞の再生治療薬候補となる可能性がある。PPARγアゴニストは炎症を抑えるだけでなく創傷治癒を促すM2マクロファージの分化を促す点から消炎治療薬となる可能性がある。